跳至主要内容
临床试验/NCT03590496
NCT03590496已完成不适用

Safety and Efficacy of PROPionatE for Reduction of LDL Cholesterol (PROPER-LDL Trial) - A Phase 2 Randomized Placebo Controlled Double-blind Trial

Charite University, Berlin, Germany2 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2018年7月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
62
试验地点
2
主要终点
LDL-cholesterol reduction

研究概览

简要总结

The objective of the trial is to evaluate a potential impact of food supplements with the short chain fatty acid propionate on blood LDL cholesterol level.

详细描述

62 patients with low cardiovascular risk will be 1:1 randomized to receive either placebo (b.i.d.) or 500mg of propionate (b.i.d.). The primary endpoint is the change (delta) in blood LDL cholesterol levels after 8 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with hypercholestrolemia and a LDL serum level of > 115 mg/dl
  • age of patient between 20 and 70 years
  • participant is fully competent and has given his/her written informed consent to the scheduled trial conduct

排除标准

  • patients with acute coronary syndrome in the last 4 weeks
  • patients with chronic symptomatic heart failure (NYHA 2-4)
  • patients with chronic renal failure and a GFR < 45 ml/min
  • patients with chronic liver disease
  • patients with hematological diseases
  • patients with severe diseases of other organ systems (tumors, infections)
  • pregnancy

结局指标

主要结局

LDL-cholesterol reduction

时间窗: 8 weeks

mg/dL

次要结局

  • non HDL(8 weeks)
  • Ratio HDL/LDL(8 weeks)
  • total cholesterol(8 weeks)
  • HDL-cholesterol(8 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Arash Haghikia

Principal Investigator

Charite University, Berlin, Germany

研究点 (2)

Loading locations...

相似试验